Indication
HER2-expressing Cancers
3 clinical trials
8 products
Product
ZanidatamabClinical trial
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Product
EvorpaceptProduct
ZW25Clinical trial
Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing CancersStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
CapecitabineProduct
TucatinibProduct
PaclitaxelProduct
VinorelbineClinical trial
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing CancersStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Product
ZW49